PO-0810: Prognostic value of lymph node-to-primary tumor standardized uptake value ratio in NPC

2020 ◽  
Vol 152 ◽  
pp. S439-S440
Author(s):  
T. Hung ◽  
J.T. Chang ◽  
C. Lin
Keyword(s):  
Lymph Node ◽  
Primary Tumor ◽  
Prognostic Value ◽  
Standardized Uptake Value

scholarly journals Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Po-Jui Chen ◽  
Wing-Keen Yap ◽  
Yu-Chuan Chang ◽  
Chen-Kan Tseng ◽  
Yin-Kai Chao ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Node ◽  
Primary Tumor ◽  
Prognostic Value ◽  
Standardized Uptake Value

scholarly journals Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy

Cancers ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 607
Author(s):  
Chia-Hsin Lin ◽  
Tsung-Min Hung ◽  
Yu-Chuan Chang ◽  
Chia-Hsun Hsieh ◽  
Ming-Chieh Shih ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Multivariate Analysis ◽  
Lymph Node ◽  
Esophageal Squamous Cell Carcinoma ◽  
Primary Tumor ◽  
Prognostic Value ◽  
Standardized Uptake Value ◽  
Definitive Chemoradiotherapy ◽  
Pet Ct ◽  
Pet Ct Scan

We aimed to investigate the prognostic value of the relative maximum standardized uptake value (SUV) of metastatic lymph node (LN) compared with that of primary tumor (SUVLN/SUVTumor) based on a pretreatment [18F]-FDG PET/CT scan in patients with clinically node-positive esophageal squamous cell carcinoma (cN+ ESCC) treated with definitive chemoradiotherapy (dCRT). We retrospectively evaluated cN+ ESCC patients who underwent a PET/CT scan before dCRT. Time-dependent receiver operating characteristics analysis was performed to identify the optimal cutoff value for SUVLN/SUVTumor. Prognostic influences of SUVLN/SUVTumor on distant metastasis-free survival (DMFS) and overall survival (OS) were evaluated using the Kaplan–Meier method and log-rank test for univariate analysis and Cox’s proportional hazards regression model for multivariate analysis. We identified 112 patients with newly diagnosed cN+ ESCC. After a median follow-up of 32.0 months, 50 (44.6%) patients had distant failure and 84 (75.0%) patients died. Patients with high SUVLN/SUVTumor (≥ 0.39) experienced worse outcomes than low SUVLN/SUVTumor (< 0.39) (two-year DMFS: 26% vs. 70%, p < 0.001; two-year OS: 21% vs. 48%, p = 0.001). Multivariate analysis showed that SUVLN/SUVTumor was an independent prognostic factor for both DMFS (adjusted HR 2.24, 95% CI 1.34–3.75, p = 0.002) and OS (adjusted HR 1.61, 95% CI 1.03–2.53, p = 0.037). Pretreatment of SUVLN/SUVTumor is a simple and useful marker for prognosticating DMFS and OS in cN+ ESCC patients treated with dCRT, which may help in tailoring treatment and designing future clinical trials.

The Prognostic Value of the Primary Tumor's Nodal Status after Surgery for Colorectal Liver Metastases in the Era of Effective Systemic Therapy

2015 ◽  
Vol 32 (3) ◽  
pp. 208-216 ◽  
Author(s):  
Eric P. van der Stok ◽  
Dirk J. Grünhagen ◽  
Wijnand J. Alberda ◽  
Maxime Reitsma ◽  
Joost Rothbarth ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Systemic Therapy ◽  
Primary Tumor ◽  
Prognostic Value ◽  
Colorectal Liver Metastases ◽  
Nodal Status ◽  
Lymph Node Status ◽  
Primary Colon

Background: The nodal status of primary colorectal cancer is of prognostic value for survival after the resection for colorectal liver metastases (CRLM). However, in the past decade, effective adjuvant chemotherapy for lymph node positive primary colon cancer was introduced. This study evaluated the prognostic value of primary lymph node status in patients with resectable metachronous CRLM in the era of effective systemic therapy. Methods: Between January 2000 and December 2011, all consecutive patients undergoing curative liver resection for CRLM were retrospectively analyzed. Overall survival (OS) was analyzed by the localization of the primary tumor (colon vs. rectum) and by lymph node status (positive vs. negative) of the primary tumor. Results: A total of 286 patients with metachronous CRLM's were selected. Five-year OS was similar for colon and rectal primaries (42 and 40%, p = 0.62). Lymph node positivity was only a prognostic factor in rectal primaries (N+ 32% vs. N0 49%, p = 0.04) and not in colon primaries (N+ 42% vs. N0 41%, p = 0.99). In multivariate analysis, these results were confirmed. Conclusion: The current study demonstrates that the nodal status of primary colon malignancies does not have prognostic value in patients undergoing resection for metachronous CRLM. A possible explanation might be the administration of effective adjuvant chemotherapy in node positive colon cancer.

The prognostic value of FDG-PET measured by standardized uptake value in patients with melanoma stage III evaluated in a prospective study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20000-e20000
Author(s):  
E. Bastiaannet ◽  
J. R. De Jong ◽  
A. H. Brouwers ◽  
A. J. Suurmeijer ◽  
H. J. Hoekstra
Keyword(s):  
Lymph Node ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Standardized Uptake Value ◽  
Disease Free Survival ◽  
Free Survival ◽  
Node Metastasis ◽  
Node Metastases ◽  
Melanoma Patients ◽  
Disease Free

e20000 Background: FDG-PET is a sensitive modality to detect melanoma metastases; melanomas are typically FDG-avid and melanoma shows an unpredictable pattern of spread. Furthermore, FDG-PET is able to quantify FDG uptake and the amount of FDG uptake, measured by the standardized uptake value (SUV), might be important for the prediction of disease specific survival (DSS) or disease free survival (DFS). Therefore, aim of this study was to perform a prospective analysis to determine whether SUV is of prognostic value in the DFS and DSS of melanoma patients with palpable lymph node metastases. Methods: From July 2002 until December 2007, all consecutive patients with palpable, histology or cytology proven lymph node metastases of melanoma referred to the University Medical Centre Groningen for examination with FDG-PET were prospectively included. The SUVmean (70% isocontour) and SUVmax in the lymph node metastasis were calculated for patients who showed no distant metastases on chest X-Ray, FDG-PET and CT. Univariate and multivariate survival analysis was performed to determine whether SUV was associated with DFS and DSS (Cox Proportional Hazard analysis). Results: Overall, 70 patients were eligible. High SUV values were present in axillary metastases (p=0.118), in patients who had more than 15 nodes removed (p=0.061) and in patients with a large tumor size in the lymph node (p=0.0001). Patients with a low SUVmean had a 3-years DFS of 54.3% as compared to 28.1% for patients with a high SUVmean (HR 2.02;p=0.051). In multivariate analysis SUVmean seems to be associated with DFS (p=0.063). DSS for patients with a high SUV was decreased, however not statistically significant (HR 1.71; p=0.182). Conclusions: The SUV in the lymph node metastasis seems to be associated with disease-free survival for melanoma patients clinically stage III. No significant financial relationships to disclose.

Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 7540-7540 ◽  
Author(s):  
Paolo Strati ◽  
Mohamed Amin Ahmed ◽  
Nathan Hale Fowler ◽  
Fredrick B. Hagemeister ◽  
Luis Fayad ◽  
...  
Keyword(s):  
Lymph Node ◽  
Follicular Lymphoma ◽  
Prognostic Value ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Standardized Uptake Value ◽  
Progression Free Survival ◽  
Response Assessment ◽  
Advanced Stage ◽  
Positron Emission

7540 Background: Positron emission tomography (PET) is recommended in follicular lymphoma (FL) for initial staging, evaluation of potential transformation, and response assessment. The prognostic value of pre-treatment PET scan has not been adequately explored. Methods: We performed a single-institution retrospective analysis of patients with advanced stage FL, without histological evidence of transformation, treated with frontline rituximab-based therapy, and analyzed the prognostic significance of baseline maximum standardized uptake value (SUVmax). Results: The median follow-up for the cohort was 94 months. Of 346 patients, 151 (44%) received R-CHOP and 195 (56%) received non-R-CHOP regimens. Among multiple single unit increments of SUVmax, a value of >18 showed the strongest association with progression-free survival (PFS) (hazard ratio [HR] 1.5, 95% confidence interval (CI) 0.95-2.3, p=0.08), and was selected as cut-off for further analysis. Fifty-two (15%) patients had a SUVmax > 18. On univariate analysis, factors associated with SUVmax > 18 were male sex (67% vs 52%, p=0.05), elevated β2-microglobulin (65% vs 47%, p=0.02), elevated LDH (37% vs 13%, p<0.001), presence of B symptoms (35% vs 14%, p=0.01), and largest lymph node ≥ 6 cm (64% vs 30%, p<0.001). On multivariate analysis, largest lymph node ≥ 6 cm was the only factor maintaining its association with SUVmax > 18 (odds ratio [OR] 2.7, 95% CI 1.3-5.3, p=0.006). SUVmax > 18 significantly associated with a lower CR rate among patients treated with non-R-CHOP regimens (45% vs 92%) (p<0.001) but not among patients treated with R-CHOP (p=1). SUVmax > 18 associated with significantly shorter PFS among patients treated with non-R-CHOP regimens (77 months vs not reached, p=0.02), but not among patients treated with R-CHOP (p=0.73). SUVmax > 18 associated with shorter overall survival (OS) both in patients treated with R-CHOP (15 year OS 70% vs 75%, p=0.02) and non-R-CHOP regimens (15 year OS 50% vs 75%, p=0.001). Conclusions: In conclusion, baseline SUVmax has prognostic value in patients with advanced stage FL receiving rituximab-based therapies. Evaluation in prospective studies is needed to further confirm these findings.

Sign in / Sign up

Export Citation Format

Share Document